Loading...
BVMF
BLAU3
Market cap415mUSD
Dec 05, Last price  
12.73BRL
1D
-5.56%
1Q
-7.82%
IPO
-67.66%
Name

Blau Farmaceutica SA

Chart & Performance

D1W1MN
BVMF:BLAU3 chart
P/E
10.41
P/S
1.29
EPS
1.22
Div Yield, %
2.86%
Shrs. gr., 5y
3.71%
Rev. gr., 5y
12.41%
Revenues
1.75b
+27.81%
383,451,000430,933,000617,658,000782,164,000977,500,0001,181,804,0001,366,407,0001,406,909,0001,372,633,0001,754,376,000
Net income
217m
-13.05%
23,062,00032,333,000103,128,000123,253,000200,238,000254,330,000325,222,000363,368,000249,809,000217,206,000
CFO
507m
+169.70%
17,061,00045,679,000126,632,00082,532,000221,290,000226,515,000153,976,000171,903,000188,060,000507,203,000
Dividend
Sep 27, 20240.08442108 BRL/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Blau FarmacĂȘutica S.A., a pharmaceutical company provides private label drugs in Brazil, Argentina, Colombia, the United States, Ecuador, Peru, and Uruguay. The company's medications cover various therapeutic classes, such as immunology, hematology, oncology, nephrology, specialties, and antibiotics. It also offers biological drugs; oral and injectable drugs for treating cancer; specialized treatments for infectious diseases; and prescription and non-prescription drugs, including dermo-medicines, condoms, and others for retail and non-retail markets. In addition, the company provides blood-derived, biological, biotechnological, and antiretroviral drugs. It serves hospitals, private clinics, chemotherapy and hemodialysis centers, and public health institutions. The company was incorporated in 1987 and is headquartered in Cotia, Brazil.
IPO date
Apr 19, 2021
Employees
Domiciled in
BR
Incorporated in
BR

Valuation

Title
BRL in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT